Although DSF/Cu used as a single treatment approach exhibited an unsatisfactory response, it efficiently enhanced the cytotoxicity of MEK inhibitors, such as PD184352 in HRASG12V-transformed zebrafish melanocytes and melanoma cells [139], UO126 in melanoma cells [137], and trametinib in 2D, 3D, and in vivo melanoma models [138], in a copper-dependent manner, as confirmed by copper chelation via the TTM. This evidence concerns the gene MAP2K7 and melanoma.